https://www.selleckchem.com/pr....oducts/Nafamostat-me
2013). A novel digital biomarker, the Altoida ADPS app, which implements gamified versions of these tests has been shown to accurately discriminate between healthy controls and individuals in prodromal stages of Alzheimer's disease (Tarnanas et al. 2013) and can differentiate between people with mild cognitive impairment who convert to Alzheimer's disease and those who don't (Tarnanas et al. 2015b). The aim of this study is the validation of a novel digital biomarker of cognitive decline.e-Health is referred to in literature
Мне нравится
Комментарий
Перепост
